AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06222034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Film-coated mini-tablets administered orally once daily
Study NCT06222034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Commercially developed film-coated tablet administered orally once daily
Study NCT06647251 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Q-MODE : radiofrequency ablation up to 50W
Description: The same device (QDOT Micro™) is used in all 3 arms of this trial. The 3 strategies of radiofrequency delivery within the 3 arms are already used in the standard of care.~For patient randomized in this arm, the device is set to Q-MODE option: the intensity of radiofrequency to isolate the pulmonary vein is limited to 50W.
Study NCT06647251 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Q-MODE+ : radiofrequency up to 90W
Description: The same device (QDOT Micro™) is used in all 3 arms of this trial. The 3 strategies of radiofrequency delivery within the 3 arms are already used in the standard of care.~For patient randomized in this arm, the device is set to Q-MODE+ option: the intensity of radiofrequency to isolate the pulmonary vein is limited to 90W.
Study NCT06647251 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hybride Q-MODE/Q-MODE+: radiofrequency ablation up to 50W in the anterior part, and 90W in the posterior part
Description: The same device (QDOT Micro™) is used in all 3 arms of this trial. The 3 strategies of radiofrequency delivery within the 3 arms are already used in the standard of care.~For patient randomized in this arm, the device is set to Q-MODE/Q-MODE+ option: the intensity of radiofrequency delivered to isolate the pulmonary vein is limited to 50W in the anterior part and to 90W in the posterior part.
Study NCT04612699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib
Description: Administered orally
Study NCT04612699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT04612699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT06209905 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar ridge augmentation
Description: Alveolar ridge augmentation in the three dimensions with either intervention; Ti-PTFE + bone mixture, or Khoury (Bone-plate) technique + bone mixture.
Study NCT06209905 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Alveolar ridge augmentation
Description: Alveolar ridge augmentation in the three dimensions with either intervention; Ti-PTFE + bone mixture, or Khoury (Bone-plate) technique + bone mixture.
Study NCT04868318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very-high protein enteral formula
Description: Peptamen® Intense VHP (37% protein)
Study NCT04868318 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard-high protein enteral formula
Description: Peptamen® (16% protein)
Study NCT05067543 — intervention group
Intervention type: DEVICE
Intervention: Tornier Perform Humeral - Stem
Description: The PERFORM Humeral System - Stem is a non-constrained prosthesis intended for the total or partial replacement of the glenohumeral articulation.
Study NCT06196073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manual therapy
Description: Bilateral oscillation therapy to the T10-L2 region for the regulation of sympathetic tone, suboccipital release technique for the regulation of parasympathetic tone, sacrum mobilization, celiac, mesenteric superior and inferior ganglion mobilizations, colon peristalsis and ileocecal valve mobilization for the treatment of functional dysfunctions, ascending colon mobilization, transverse colon. mobilization, descending colon fascia mobilization and sigmoid colon mobilization, peritoneal mobilization
Study NCT06196073 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: conservative treatment
Description: Nutritional recommendations and necessary nutritional supplements to facilitate digestion and defecation
Study NCT06401785 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrogen capsules
Description: In experiment group, participants will receive 2 solid hydrogen capsules every day for 24 weeks. In control group, participants will receive 2 capsules not containing hydrogen every day for 24 weeks.
Study NCT06401785 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Hydrogen capsules
Description: In experiment group, participants will receive 2 solid hydrogen capsules every day for 24 weeks. In control group, participants will receive 2 capsules not containing hydrogen every day for 24 weeks.
Study NCT05205252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazemetostat
Description: Orally, twice daily in continuous 28-day cycles.
Study NCT05205252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tafasitamab
Description: Intravenously, 12 mg/kg, once daily on Cycle 1: Days 1, 4, 8, 15 and 22 of the 28-day cycle. Cycles 2 and 3: Days 1, 8, 15 and 22 of each 28-day cycle. Cycle 4 and beyond: Days 1 and 15 of each 28-day cycle.
Study NCT05205252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Orally, 10 mg or 20 mg based on kidney function, once daily from Days 1 to 21 of continuous 28-day cycles for up to 12 cycles.
Study NCT05205252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acalabrutinib
Description: Orally, 100 mg, twice daily.
Study NCT05205252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab (Intravenously)
Description: Intravenously, 16 mg/kg actual body weight, once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.
Study NCT05205252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mosunetuzumab
Description: Subcutaneously, step-up doses on Cycle 1 Days 1 (5 mg), 8 (45 mg) and 15 (45 mg) and then 45 mg from Cycle 2 through 12 on Day 1 of the 28-day cycle.
Study NCT05205252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab (Subcutaneously)
Description: Subcutaneously, 1800 mg, once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.
Study NCT05205252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronidase-Fihj
Description: Subcutaneously, 30,000 units, once daily on Cycles 1 and 2: Days 1, 8, 15 and 22 of the 28-day cycle. Cycles 3 through 6: Days 1 and 15 each 28-day cycle. Cycle 7 and beyond: Day 1 of each 28-day cycle.
Study NCT05205252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Orally, 4 mg, once daily on Days 1 to 21 of continuous 28-day cycles.
Study NCT05205252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 20mg
Description: Orally, 20 mg or 40 mg, once daily on Days 1, 8, 15, and 22 of continuous 28-day cycles.
Study NCT05427019 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal adductor canal block
Description: All catheters were inserted under a full aseptic technique using a real-time ultrasound-guided in-plane approach by an experienced anesthesiologist. The adductor canal catheter is inserted 2cm above the adductor hiatus.
Study NCT05427019 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal adductor canal block and Periarticular block
Description: All catheters were inserted under a full aseptic technique using a real-time ultrasound-guided in-plane approach by an experienced anesthesiologist. The adductor canal catheter is inserted 2cm above the adductor hiatus.The periarticular injection solution contained 20mL of 7.5 mg/mL ropivacaine, 30mg of ketorolac, and 0.3mL of 1.0 mg/mL epinephrine. These agents were mixed with normal saline to a combined volume of 50mL. The surgeon injected this mixture into the tensor fascia lata, subcutaneous tissues, abductors, short external rotators muscles, and structures in the capsule.
Study NCT05861778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-Girentuximab
Description: A single administration of 37 MBq (±10%) 89Zr-TLX250, containing a mass dose of 10 mg of girentuximab, followed by whole body PET/CT scans were performed at 0.5h, 4h, 24h, 72 hours and 7±1 days post administration.
Study NCT06295887 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Program using VR or simulator designed to improve medical intern's performance managing emergency situation
Description: Simulation program using VR or simulator that mimics patient's desaturation
Study NCT06295887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Program using VR or simulator designed to improve medical intern's performance managing emergency situation
Description: Simulation program using VR or simulator that mimics patient's desaturation
Study NCT06320041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose oxelidine group
Description: Analgesic dose
Study NCT06320041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose oxelidine group
Description: Analgesic dose
Study NCT06320041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone group
Description: Analgesic dose
Study NCT06090097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KneeBRIGHT System
Description: The KneeBRIGHT system includes electromyogram sensors and video game software that leads participants through physical therapy exercise.
Study NCT06090097 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Exercise
Description: The control group will complete a 10-week regimen of conventional PT exercise
Study NCT05294991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness app intervention #1
Description: This is the active intervention group.
Study NCT05294991 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness app intervention #2
Description: This is the active comparator/control group.
Study NCT05209841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose heparin
Description: Catheters will be sealed with 3 mL of Fibrillin Ⓡ (heparin 20UI/mL)
Study NCT05209841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Catheters will be sealed with 3mL of 0.9% sodium chloride
Study NCT05432050 — intervention group
Intervention type: DEVICE
Intervention: Bispectral index and Patient state index monitoring
Description: The depth of anesthesia will be monitored with both the bispectral index and patient state index at the same time.
Study NCT04936698 — intervention group
Intervention type: DRUG
Intervention: PTU 50 MG Oral Tablet
Description: to treat if the patient has hyperthyroidism
Study NCT04936698 — intervention group
Intervention type: DRUG
Intervention: Levothyroxin
Description: to treat if the patient has hypothyroidism
Study NCT06250634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole + amoxicillin
Description: esomeprazole enteric-coated tablets (AstraZeneca) 20mg four times daily and amoxicillin capsules (Hainan General Sanyang Pharmaceutical) 750mg four times daily
Study NCT06250634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole + amoxicillin + clarithromycin + colloidal bismuth tartrate agent
Description: 20mg twice daily of esomeprazole enteric-coated tablets, 1000 mg twice daily of amoxicillin capsules, 500 mg twice daily of clarithromycin sustained-release tablets (Henan Fusen Pharmaceutical) and 165 mg three times daily of colloidal bismuth tartrate capsules (Shanxi Xinbaoyuan Pharmaceutical)
Study NCT06250634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan + amoxicillin
Description: 20 mg twice daily of vonoprazan fumarate tablets (Takeda Pharmaceutical Company Limited) and 1000 mg three times daily of amoxicillin capsules (Hainan General Sanyang Pharmaceutical)
Study NCT06250634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan + amoxicillin + clarithromycin
Description: 20 mg twice daily of vonoprazan fumarate tablets, 1000 mg twice daily of amoxicillin capsules and 500 mg twice daily of clarithromycin sustained-release tablets (Henan Fusen Pharmaceutical)
Study NCT05721209 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Mill with AR/VR Guidance
Description: Treadmill training system that is a combination of an instrumented treadmill, front display, and a floor projector, allowing functional gait and balance training. The AR/VR feedback will include computer generated obstacles and objects projected as images on the treadmill. Participants will be asked to use these projections as stepping cues and step on some images of objects while avoiding stepping on the images of obstacles.
Study NCT05582369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affective Rewards Messages
Description: Messages about the affective rewards of exercise
Study NCT05409079 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abilitech Assist
Description: The Abilitech™ Assist is an externally worn device supported by a body frame, which is designed to support and assist the arms in activities of daily living (ADL's). The Abilitech Assist is comprised of three parts: a modular body vest that adjusts to accommodate different body sizes, a single arm orthosis that attaches to the body vest, and an external power pack and controller for tensioning the arm's internal springs to adjust the arm's level of assist. The device augments a user's native arm function to provide lift assistance. Software customizes the spring tension for the level of assist required. The user can turn the system ON/OFF and toggle and adjust the level of assist (e.g., low, medium or high assist) using a pushbutton controller.
Study NCT04857918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual running group program
Description: The intervention will include an eight-week virtual running group program hosted on online platforms such as Zoom and the fitness application Strava. Participants will be placed in running groups of 6 people, and each running group will have the collective goal to run/walk the distance across the province of B.C., (940 km) and will meet weekly over Zoom to socialize and discuss running topics and their progress towards the group goal. Participants will receive a t-shirt with the STRIDE logo and a phone armband for carrying their smart phone during runs and walks.
Study NCT04857918 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control: Fitness Application Strava
Description: The attention control condition will be instructed to record their exercise using the Strava application, and will be encouraged to participate in 150 minutes of moderate-to-vigorous exercise each week of the intervention.
Study NCT04156945 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural intervention
Description: An online tailored behavioural intervention. The intervention will be developed as part of the project and will be based on the principles of the Information-Motivation-Behavioural Skills (IBM) model for behavioural change. It will consist of four interactive text-based modules, and demonstration and modelling videos addressing information, motivation, and behavioural skills. The intervention will be offered on a website and able to be used on PCs as well as any mobile device. It will be provided to the participants after randomization at month 6 and available for a total period of 18 months.
Study NCT04156945 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HCV RNA home-based test
Description: An additional patient-initiated home-based HCV testing service. The service offers a maximum of 4 free-of-charge HCV-RNA tests, which involves HCV testing using self-sampled dried blood spots (DBS). The DBS obtained from a finger stick will be used for HCV-RNA testing in the laboratory. DBS test kits, along with instructions and package materials for returning the test kits with the self-collected DBS sample will be provided to the participants after randomization at month 6 and available for use for a total period of 18 months.
Study NCT05721209 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-Mill without AR/VR Guidance
Description: Treadmill training system that is a combination of an instrumented treadmill, front display, and a floor projector, allowing functional gait and balance training.
Study NCT05721209 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zeno 3-Layer Walkway
Description: Used to conduct mobility assessments to assess temporal and spatial gait parameters during the 6-minute walk test.
Study NCT05721209 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zeno 3-Layer Walkway
Description: Used to conduct mobility assessments to assess temporal and spatial gait parameters during the 6-minute walk test.
Study NCT05721209 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hunova
Description: Used to conduct fall-risk assessment.
Study NCT05721209 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hunova
Description: Used to conduct fall-risk assessment.
Study NCT06355128 — intervention group
Intervention type: OTHER
Intervention: NOT
Description: NOT
Study NCT05727488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will be asked to practice home exercises every day of the week for 12 weeks. The SARAH exercise program consists of 7 mobility and 4 strengthening exercises. Progress will be made by increasing the repetitions and duration of the exercises every week.
Study NCT05300997 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker blood draw and saliva collection
Description: Three peripheral 10mL blood sample (if available) Three 1 - 3mL salivary samples (if available)
Study NCT05934656 — intervention group
Intervention type: OTHER
Intervention: Latent class analysis
Description: The investigators will conduct a longitudinal study comprising nested groups A to C of the study population, with progressively more detailed mechanistic investigations. No control group.~Group A will complete a CF-specific measure of gut symptoms (CFAbd-Score), a generic constipation score (PAC-SYM) and 24 hour dietary recall (Intake24).~Group B will have stool and blood for microbiome, inflammatory mediators and faecal fat.~Group C will have gut MRI and exploratory studies of inflammation.
Study NCT05483894 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin 10mg
Description: Atorvastatin 10mg(Lipinon Tab. 10mg) once daily for 24 weeks for experimental group
Study NCT05483894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 10mg
Description: Atorvastatin 10mg(Lipinon Tab. 10mg) once daily for 24 weeks for experimental group
Study NCT05483894 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 12 weeks and than Atorvastatin(Lipinon Tab. 10mg) for 12 weeks for control group
Study NCT05787366 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: usual care and follow-up by a nurse
Description: follow-up by a nurse and referral to a specialist(s) according to symptoms
Study NCT05787366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Multifactorial Intervention (IMP)
Description: The content of the intervention is defined according to the result of the initial assessment in relation to the person's needs and the nature of his or her persistent symptoms. The patient, depending on his or her needs, may choose to participate in the following workshops :~* Knowledge of the disease and specific management, (led by the nurse)~* Covid-19 and anxiety/depression, (psychologist)~* Fatigue and adapted physical activities (video capsules)~* Covid-long and social link (professional and voluntary activities...) (social worker and/or nurse)~* The Recovery Café aims to provide a space for patients to listen to each other and share their experiences around themes related to the different dimensions of recovery: medical and psychological, economic, professional, social and existential.
Study NCT06045442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise training
Description: The patients in the intervention group will receive 3 months of endurance training, 2x/week for 30 min. 5 min of this should be a warm-up, 20 min of exertion and 5 min of cool down. The warm-up and cool-down should be equivalent to a very light load (Borg scale 9), whereas the exertion phase should be exhausting for the patients (Borg scale 14-15).
Study NCT06045442 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Usual care
Study NCT05697250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser power settings (Thulium Fiber Laser)
Description: Ureteroscopic lithotripsy using low power laser settings (0.4 - 0.6 J at 10 Hz corresponding to 2.4 - 6.0 Watts) or high power laser settings (0.4 J at 40 Hz, 0.6 J at 30 Hz or 0.8 J at 20 Hz corresponding to 16 - 18 Watts).
Study NCT05201040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JETKNEE Synovial Fluid Supplement
Description: 2mL of JETKNEE Synovial Fluid Supplement
Study NCT05201040 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 2mL of normal saline